Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

Thumbnail

Dapagliflozin still beneficial for HFpEF, HFmrEF patients with AFib

While some heart failure medications are less effective in patients with concomitant atrial fibrillation, new research suggests that is not the case for dapagliflozin.

Thumbnail

FDA announces new recall of blood pressure medication due to potential cancer risk

Patients impacted by this recall are advised to speak with a physician about how to proceed. 

vaccine child kid young patient covid-19 mask patient

Heart damage after COVID-19 vaccination extremely rare among adolescents

Vaccine-related myocarditis was seen in approximately 0.00005% of children between the ages of 12 and 15. All cases were mild, and the median length of stay at the hospital was three days. 

Doctor patient with masks

COVID-19 drug Paxlovid may react poorly with certain heart medications, cardiologists warn

Nirmatrelvir-ritonavir, sold by Pfizer under the name Paxlovid, is commonly prescribed to treat COVID-19. When treating some heart patients, however, physicians may want to consider an alternative approach.

Thumbnail

Apixaban outperforms rivaroxaban when treating patients with AFib and valvular heart disease

Researchers explored data from nearly 20,000 patients, sharing their findings in Annals of Internal Medicine.

Deepak Bhatt, MD, MPH, executive director of the interventional cardiovascular programs at Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, explained the new generation of cholesterol lowering agents and their roles in various types of patients.

VIDEO: Deepak Bhatt discusses the role of new cholesterol-lowering agents

Deepak Bhatt, MD, a professor of medicine at Harvard Medical School, details the new generation of cholesterol-lowering agents and their roles in patient care. 

Leading cardiologists sound the alarm, say polypills could save millions of lives if made widely available

“This systemic failure is a global tragedy, as many premature deaths from CVD could be avoided,” one cardiologist said. 

New evidence that heart damage risk is much higher after COVID-19 infection than after vaccination

The new meta-analysis, published in Frontiers in Cardiovascular Medicine, included data from 58 million patients. “We hope our findings will help mitigate vaccine hesitancy and increase vaccine uptake," one researcher said. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.